FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281652688> ?p ?o ?g. }

• W4281652688 endingPage "7561" @default.
• W4281652688 startingPage "7561" @default.
• W4281652688 abstract "7561 Background: PN is an identified risk of anti-microtubule agents, including polatuzumab vedotin and vincristine. POLARIX (NCT03274492), a Phase III randomized, double-blind, placebo-controlled study comparing Pola-R-CHP with R-CHOP, demonstrated improved progression-free survival (PFS) with Pola-R-CHP (Tilly et al. NEJM 2022). Here, we evaluate the impact of Pola-R-CHP vs R-CHOP on PN using ClinRO and PRO data. Methods: Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) received Pola-R-CHP or R-CHOP. ClinRO data were based on PN grading according to the NCI CTCAE v4.0. PRO data were generated from assessment of patient-reported PN symptoms at baseline and Day 1 of each cycle using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (FACT-GOG/NTX) subscale, ranging from 0–44, with higher scores representing lower levels of PN (minimal clinically important difference: 1.38–3.68 [Cheng et al. Health Qual Life Outcomes 2020]). Results: At baseline, ClinRO and PRO symptom scores showed low PN burden (Table). Overall incidence of PN was comparable between treatment arms (Pola-R-CHP: 52.9%; R-CHOP: 53.9%); most events were grade 1, and incidence of grade 2 (Pola-R-CHP: 12.2%; R-CHOP: 15.5%) and grade 3 (Pola-R-CHP: 1.6%; R-CHOP: 1.1%) events were comparable between treatment arms. FACT-GOG/NTX survey completion was high in both arms (96% at baseline; >80% at other timepoints). When evaluated by cycle, ClinRO and PRO demonstrated that more patients experienced earlier onset PN with R-CHOP than with Pola-R-CHP (Table), with ̃10% more R-CHOP- than Pola-R-CHP-treated patients having clinician-reported PN in Cycle (C) 2–5, and a ̃+1-point difference (i.e. fewer symptoms) in PRO symptom scores in C3–6 with Pola-R-CHP vs R-CHOP; by C8+, and during follow up, rates and symptoms of PN were similar. PN symptoms resulted in fewer dose reductions (3.9% vs 8.2%) and drug discontinuations (0.7% vs 2.1%) with Pola-R-CHP vs R-CHOP. Duration of PN was similar for both treatments. Conclusions: In the POLARIX study, Pola-R-CHP did not result in different rates or severity of PN vs R-CHOP. According to ClinRO and PRO data, PN occurred later following initial exposure to Pola-R-CHP than to R-CHOP, and there were fewer dose modifications with Pola-R-CHP than with R-CHOP. Overall, the risk of PN was manageable. Clinical trial information: NCT03274492. [Table: see text]" @default.
• W4281652688 created "2022-06-13" @default.
• W4281652688 creator A5000959540 @default.
• W4281652688 creator A5003078312 @default.
• W4281652688 creator A5010046270 @default.
• W4281652688 creator A5016764336 @default.
• W4281652688 creator A5020311627 @default.
• W4281652688 creator A5020699813 @default.
• W4281652688 creator A5031041032 @default.
• W4281652688 creator A5040518471 @default.
• W4281652688 creator A5045381939 @default.
• W4281652688 creator A5048206869 @default.
• W4281652688 creator A5050239426 @default.
• W4281652688 creator A5055086899 @default.
• W4281652688 creator A5058170926 @default.
• W4281652688 creator A5060982767 @default.
• W4281652688 creator A5061466414 @default.
• W4281652688 creator A5082892912 @default.
• W4281652688 creator A5088476247 @default.
• W4281652688 creator A5088962433 @default.
• W4281652688 creator A5090512266 @default.
• W4281652688 creator A5091800861 @default.
• W4281652688 date "2022-06-01" @default.
• W4281652688 modified "2023-10-14" @default.
• W4281652688 title "Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study." @default.
• W4281652688 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.7561" @default.
• W4281652688 hasPublicationYear "2022" @default.
• W4281652688 type Work @default.
• W4281652688 citedByCount "0" @default.
• W4281652688 crossrefType "journal-article" @default.
• W4281652688 hasAuthorship W4281652688A5000959540 @default.
• W4281652688 hasAuthorship W4281652688A5003078312 @default.
• W4281652688 hasAuthorship W4281652688A5010046270 @default.
• W4281652688 hasAuthorship W4281652688A5016764336 @default.
• W4281652688 hasAuthorship W4281652688A5020311627 @default.
• W4281652688 hasAuthorship W4281652688A5020699813 @default.
• W4281652688 hasAuthorship W4281652688A5031041032 @default.
• W4281652688 hasAuthorship W4281652688A5040518471 @default.
• W4281652688 hasAuthorship W4281652688A5045381939 @default.
• W4281652688 hasAuthorship W4281652688A5048206869 @default.
• W4281652688 hasAuthorship W4281652688A5050239426 @default.
• W4281652688 hasAuthorship W4281652688A5055086899 @default.
• W4281652688 hasAuthorship W4281652688A5058170926 @default.
• W4281652688 hasAuthorship W4281652688A5060982767 @default.
• W4281652688 hasAuthorship W4281652688A5061466414 @default.
• W4281652688 hasAuthorship W4281652688A5082892912 @default.
• W4281652688 hasAuthorship W4281652688A5088476247 @default.
• W4281652688 hasAuthorship W4281652688A5088962433 @default.
• W4281652688 hasAuthorship W4281652688A5090512266 @default.
• W4281652688 hasAuthorship W4281652688A5091800861 @default.
• W4281652688 hasConcept C120665830 @default.
• W4281652688 hasConcept C121332964 @default.
• W4281652688 hasConcept C126322002 @default.
• W4281652688 hasConcept C142724271 @default.
• W4281652688 hasConcept C143998085 @default.
• W4281652688 hasConcept C204787440 @default.
• W4281652688 hasConcept C27081682 @default.
• W4281652688 hasConcept C2776694085 @default.
• W4281652688 hasConcept C2776755627 @default.
• W4281652688 hasConcept C2779338263 @default.
• W4281652688 hasConcept C2779429289 @default.
• W4281652688 hasConcept C2779725641 @default.
• W4281652688 hasConcept C2780739268 @default.
• W4281652688 hasConcept C61511704 @default.
• W4281652688 hasConcept C71924100 @default.
• W4281652688 hasConcept C90924648 @default.
• W4281652688 hasConceptScore W4281652688C120665830 @default.
• W4281652688 hasConceptScore W4281652688C121332964 @default.
• W4281652688 hasConceptScore W4281652688C126322002 @default.
• W4281652688 hasConceptScore W4281652688C142724271 @default.
• W4281652688 hasConceptScore W4281652688C143998085 @default.
• W4281652688 hasConceptScore W4281652688C204787440 @default.
• W4281652688 hasConceptScore W4281652688C27081682 @default.
• W4281652688 hasConceptScore W4281652688C2776694085 @default.
• W4281652688 hasConceptScore W4281652688C2776755627 @default.
• W4281652688 hasConceptScore W4281652688C2779338263 @default.
• W4281652688 hasConceptScore W4281652688C2779429289 @default.
• W4281652688 hasConceptScore W4281652688C2779725641 @default.
• W4281652688 hasConceptScore W4281652688C2780739268 @default.
• W4281652688 hasConceptScore W4281652688C61511704 @default.
• W4281652688 hasConceptScore W4281652688C71924100 @default.
• W4281652688 hasConceptScore W4281652688C90924648 @default.
• W4281652688 hasIssue "16_suppl" @default.
• W4281652688 hasLocation W42816526881 @default.
• W4281652688 hasOpenAccess W4281652688 @default.
• W4281652688 hasPrimaryLocation W42816526881 @default.
• W4281652688 hasRelatedWork W160156331 @default.
• W4281652688 hasRelatedWork W2023821223 @default.
• W4281652688 hasRelatedWork W2029178599 @default.
• W4281652688 hasRelatedWork W2092993480 @default.
• W4281652688 hasRelatedWork W2158035792 @default.
• W4281652688 hasRelatedWork W2178567417 @default.
• W4281652688 hasRelatedWork W2341955287 @default.
• W4281652688 hasRelatedWork W4312173599 @default.
• W4281652688 hasRelatedWork W2159407751 @default.
• W4281652688 hasRelatedWork W2183308400 @default.
• W4281652688 hasVolume "40" @default.
• W4281652688 isParatext "false" @default.

• next